Skip to main content
ISTH 2023 Main banner
Back

    Oral Communication

    COVID

    Risk Factors and Treatment in COVID-19

    OC 05.1 - Impact of low molecular weight heparin (LMWH) on SARS-CoV2 infection: HEPARIN-SARS-CoV2 clinical trial.

    Saturday, June 24, 2023
    13:00 – 13:15 ET
    Room: 511
    Session Available As: On-Demand
    Background: There are biological foundations that support the beneficial immunomodulatory role, not anticoagulant, of LMWH in SARS-CoV2 infection.

    Aims: The main objective of the Heparin-SARS-CoV2 study was to assess the impact of treatment with LMWH on the escalation of oxygen therapy or the need for invasive mechanical ventilation or mortality in patients admitted with SARS-CoV2 infection.

    Methods: Independent, non-commercial, multicenter, randomized clinical trial of patients
    consecutive hospitalized for SARS-CoV2 infection. Patients are randomized to either
    experimental group, enoxaparin 1 mg/kg/day, or control group, enoxaparin 40mg/sc/day, for 14 days. After this period, the responsible physician assessed the risk/benefit of whether or not to extend the prophylaxis with enoxaparin 40mg/sc/day. All patients were followed up for 60 days. The primary efficacy event was the set of need for oxygen therapy escalation or invasive mechanical ventilation or mortality during admission. Secondary efficacy events were need for rescue medication (eg, parenteral corticosteroids, tocilizumab) and length of hospitalization. The hemorrhages were the primary safety variable.

    Results: We have analyzed 138 patients whose median age was 55 years (IQR: 15.6), 38% were women.
    Table 1 shows the main clinical characteristics of the included patients. The results on efficacy and safety events are summarized in Table 2.

    Conclusion(s): No differences were found in the evolution of COVID between the two treatment groups for the profile of patients included in the trial. The increase in LMWH at an intermediate dose does not contribute benefits in a profile of patients with COVID who required hospitalization, but who had a favorable evolution in most of them.
    (Eudra number: 2020-001891-14)
    Financing: Respira Foundation (SEPAR 1128), Neumosur Foundation and grant from Sociedad Española de Trombosis y Hemostasia (SETH)

    Learning Objectives:

    • To discuss the basis of the clinical trial about the impact of LMWH in the COVID19 infection.
    • To examine the results of the clinical trial about the impact of LMWH in the COVID19 infection.
    • To interpret the results of the clinical trial about the impact of LMWH in the COVID19 infection.